Your browser doesn't support javascript.
loading
Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.
Penny Moore; Thandeka Moyo; Tandile Hermanus; Prudence Kgagudi; Frances Ayres; Zanele Makhado; Jerald Sadoff; Mathieu Le Gars; Griet van Roey; Carol Crowther; Nigel Garrett; Linda-Gail Bekker; Lynn Morris; Hanneke Schuitemaker; Glenda Gray.
Afiliación
  • Penny Moore; University of the Witwatersrand
  • Thandeka Moyo; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Tandile Hermanus; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Prudence Kgagudi; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
  • Frances Ayres; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
  • Zanele Makhado; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa.
  • Jerald Sadoff; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Mathieu Le Gars; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Griet van Roey; Janssen Vaccines and Prevention, Leiden, the Netherlands.
  • Carol Crowther; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Nigel Garrett; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa
  • Linda-Gail Bekker; Desmond Tutu HIV Centre, Cape Town, South Africa
  • Lynn Morris; National Institute for Communicable Diseases of the National Health Laboratory Service (NHLS), Johannesburg, South Africa
  • Hanneke Schuitemaker; Janssen Vaccines and Prevention, Leiden, the Netherlands
  • Glenda Gray; South African Medical Research Council, Cape Town, South Africa
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-447722
ABSTRACT
The emergence of SARS-CoV-2 variants, such as 501Y.V2, with immune evasion mutations in the spike has resulted in reduced efficacy of several COVID-19 vaccines. However, the efficacy of the Ad26.COV2.S vaccine, when tested in South Africa after the emergence of 501Y.V2, was not adversely impacted. We therefore assessed the binding and neutralization capacity of n=120 South African sera (from Day 29, post-vaccination) from the Janssen phase 3 study, Ensemble. Spike binding assays using both the Wuhan-1 D614G and 501Y.V2 Spikes showed high levels of cross-reactivity. In contrast, in a subset of 27 sera, we observed significantly reduced neutralization of 501Y.V2 compared to Wuhan-1 D614G, with 22/27 (82%) of sera showing no detectable neutralization of 501Y.V2 at Day 29. These data suggest that even low levels of neutralizing antibodies may contribute to protection from moderate/severe disease. In addition, Fc effector function and T cells may play an important role in protection by this vaccine against 501Y.V2.
Licencia
cc_by_nc
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Rct Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Tipo de estudio: Rct Idioma: En Año: 2021 Tipo del documento: Preprint